New funds to fortify US market entry and growth strategy, as well as advance breakthrough research

加强美国市场进入和增长战略的新资金，以及推进突破性研究

CAMBRIDGE, Mass., Dec. 18, 2023 /PRNewswire/ -- Biorithm, a global women's health medtech, has closed $3.5 million in Series A funding, co-led by Adaptive Capital Partners and SEEDS Capital. With a homegrown spirit and a global vision, Biorithm is dedicated to developing cutting-edge solutions for personalized connected maternity care.

马萨诸塞州剑桥，2023年12月18日/PRNewswire/--全球女性健康医疗技术公司Biorithm在Adaptive Capital Partners和SEEDS Capital的共同领导下，完成了350万美元的a系列资金。凭借本土精神和全球视野，Biorithm致力于为个性化关联产妇护理开发前沿解决方案。

The funding will fuel Biorithm's expansion in Southeast Asia and the United States. It also will assist the company in advancing Femom, a comprehensive obstetric remote monitoring solution, and completing clinical studies to support a 510(K) premarket submission to the US Food and Drug Administration. .

这笔资金将推动Biorithm在东南亚和美国的扩张。它还将帮助该公司推进Femom，一种全面的产科远程监测解决方案，并完成临床研究，以支持510（K）上市前提交给美国食品和药物管理局。。

Complications from childbirth result in mortality for 800 women every day. Biorithm is committed to ending preventable pregnancy complications by pioneering new standards of care through protocol-based remote monitoring of maternal and fetal biometrics. Biorithm's Femom is patient-friendly technology that facilitates patient monitoring, accessible personalized guidance, and seamless integration of predictive analytics that help clinicians to identify early signs of complication..

分娩并发症每天导致800名妇女死亡。Biorithm致力于通过基于协议的孕产妇和胎儿生物特征远程监测，开创新的护理标准，从而终止可预防的妊娠并发症。Biorithm的Femom是一种对患者友好的技术，可促进患者监测，可访问的个性化指导以及预测分析的无缝集成，从而帮助临床医生识别并发症的早期迹象。。

Julian Robinson, Chairman of Biorithm Medical Advisory Board, highlighted the significance of this technology, that will offer enhanced accessibility and improved healthcare outcomes. He further emphasized, 'Biorithm will enhance care, minimize inconvenience, and reduce cost for patients and improve the efficiency and effectiveness of the clinical health care provider.

Biorithm医学咨询委员会主席朱利安·罗宾逊（JulianRobinson）强调了这项技术的重要性，它将提供增强的可访问性和改善的医疗保健效果。他进一步强调，“Biorithm将加强护理，最大程度地减少不便，降低患者成本，提高临床医疗保健提供者的效率和有效性。

Above all, it will improve medical outcomes for mothers and their babies.'.

最重要的是，它将改善母亲及其婴儿的医疗结果。”。

With headquarters in Singapore and Massachusetts, Biorithm aims to strengthen the women's health ecosystem globally. Amrish Nair, Founder and CEO, expressed gratitude for investor support, envisioning a future where every expectant mother has proactive and connected healthcare. The funding from new investor Adaptive Capital Partners and existing investor SEEDS Capital reaffirms their recognition of Biorithm's pivotal role in reshaping women's healthcare through innovative technology..

Biorithm总部位于新加坡和马萨诸塞州，旨在加强全球女性健康生态系统。创始人兼首席执行官阿姆利什·奈尔（AmrishNair）对投资者的支持表示感谢，并设想了一个未来，每个准妈妈都能拥有积极主动、相互关联的医疗保健。新的投资者适应性资本合作伙伴和现有投资者种子资本提供的资金重申了他们对Biorithm在通过创新技术重塑女性医疗保健方面的关键作用的认可。。

'We are truly heartened to have the support of our new and existing investors. We feel a deep commitment to improving the health of expectant mothers and putting an end to preventable complications. There is a collapse of maternal care driven by socio-economic factors and limitation of current monitoring technologies in many regions across the world, and we are hard at work to solve this problem in partnership with others.

“我们真的很高兴得到新投资者和现有投资者的支持。我们深切地致力于改善孕妇的健康状况，结束可预防的并发症。在世界许多地区，由于社会经济因素和当前监测技术的局限性，孕产妇保健崩溃，我们正在努力与其他人合作解决这一问题。

The investment we have received is a testament to our mission at Biorithm, and a future where every expectant mother has access to healthcare that is not only proactive but profoundly connected to her unique journey,' Amrish Nair, Founder and CEO, Biorithm..

Biorithm创始人兼首席执行官阿姆利什·奈尔（AmrishNair）说，我们收到的投资证明了我们在Biorithm的使命，也是一个未来，每个准妈妈都可以获得医疗保健，这不仅是积极的，而且与她独特的旅程有着深刻的联系。。

Having successfully completed clinical trials with healthcare institutions in Singapore and the United Kingdom, Biorithm will be expanding its clinical trial footprint to more priority markets. Biorithm is also channeling its incoming funding into further research that demonstrates how remote care can be most effectively deployed.

在新加坡和英国的医疗机构成功完成临床试验后，Biorithm将把其临床试验足迹扩大到更优先的市场。Biorithm还将其获得的资金用于进一步的研究，以证明如何最有效地部署远程护理。

In its aim to strengthen the overall women's health ecosystem, Biorithm will chart out and foster key partnerships with various stakeholders globally to improve maternal and baby health through data, personalized and accessible care..

为了加强整个妇女健康生态系统，Biorithm将与全球各利益相关者建立关键合作伙伴关系，通过数据、个性化和可获得的护理改善母婴健康。。

'Building a system of connected medical care is crucial to help clinicians predict, diagnose, and formulate calculated decisions on early intervention to prevent complications and devise treatments. We are excited with our investment into Biorithm as the company is focused on creating measurable and actionable value in maternal health, integrating this system across all touchpoints to ensure safety throughout the pregnancy journey,' said Shi Ying, Founder & Managing Partner, Adaptive Capital Partners.

“建立一个相互关联的医疗保健系统对于帮助临床医生预测，诊断和制定早期干预的计算决策至关重要，以预防并发症并设计治疗方法。Adaptive Capital Partners创始人兼管理合伙人石英（Shi Ying）表示，我们对Biorithm的投资感到兴奋，因为该公司专注于在孕产妇健康方面创造可衡量和可行的价值，将该系统整合到所有接触点，以确保整个怀孕过程的安全。

Tan Kaixin, General Manager, SEEDS Capital added, 'By leveraging technology to enable remote monitoring, Biorithm's offering provides enhanced access to quality care for expectant mothers. We are excited to continue backing Biorithm as they accelerate their commercialization in the US and support their vision of revolutionizing the global maternal health market.

种子资本（SEEDS Capital）总经理谭开新补充道，“通过利用技术实现远程监测，Biorithm的产品为孕妇提供了更好的优质护理服务。我们很高兴继续支持Biorithm，因为他们加速了其在美国的商业化，并支持他们彻底改变全球孕产妇保健市场的愿景。

Investments in MedTech startups like Biorithm will propel the healthcare ecosystem to new heights.'.

对Biorithm等医疗科技初创公司的投资将推动医疗保健生态系统达到新的高度。”。

About Biorithm

关于Biorithm

Biorithm envisions a world with better access to maternal care and improved outcomes for mother and child. To achieve this, Biorithm has developed a remote maternal-fetal care platform with novel intellectual property in device and algorithms. Having grown from academia, Biorithm is now present globally, working with clinical partners to deliver better care for mothers and babies.

Biorithm设想了一个更好地获得孕产妇护理和改善母婴结局的世界。为了实现这一目标，Biorithm开发了一个远程母胎护理平台，该平台在设备和算法方面具有新颖的知识产权。Biorithm从学术界成长而来，现在已经遍布全球，与临床合作伙伴合作，为母亲和婴儿提供更好的护理。

For more information, visit https://www.bio-rithm.com.

For more information, visithttps://www.bio-rithm.com.

About SEEDS Capital

关于种子资本

As the investment arm of Enterprise Singapore, SEEDS Capital catalyses smart investments into innovative Singapore-based early-stage startups with strong intellectual content and global market potential. We adopt a co-investment model, working hand in hand with institutional investors from around the world.

作为新加坡企业（Enterprise Singapore）的投资部门，种子资本（SEEDS Capital）为新加坡的创新型早期创业公司（具有强大的知识含量和全球市场潜力）提供智能投资。我们采用共同投资模式，与世界各地的机构投资者携手合作。

Leveraging our collective expertise and networks, we help startups commercialise, realise their business development plans, and expand globally. We focus our investments into emerging and strategic sectors aligned with national priorities, including Manufacturing, Trade & Connectivity, Human Health & Potential, Urban Solutions & Sustainability, and Smart Nation & Digital Economy..

利用我们的集体专业知识和网络，我们帮助初创公司商业化，实现其业务发展计划，并在全球范围内扩张。我们将投资重点放在符合国家优先事项的新兴和战略性行业，包括制造业、贸易与互联互通、人类健康与潜力、城市解决方案与可持续性、智慧国家与数字经济。。

About Adaptive Capital Partners

关于Adaptive Capital Partners

Adaptive Capital Partners is a Singapore based, early-stage technology focused venture capital firm. Adaptive invests in high conviction and disruptive technology startups with a predominant focus in HealthTech and MedTech while working with founders in many of their defining challenges with the team's deep experience as an operator and research background..

Adaptive Capital Partners是一家总部位于新加坡的早期科技风险投资公司。Adaptive投资于高信念和颠覆性的技术初创公司，主要专注于HealthTech和MedTech，同时与创始人合作，解决他们作为运营商和研究背景的丰富经验带来的许多决定性挑战。。

SOURCE Biorithm

源生物学